| ²é¿´: 1244 | »Ø¸´: 3 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
ÒøÉþľ³æ (ÖøÃûдÊÖ)
Ö²Îï²ËÄñ
|
[ÇóÖú]
¹ØÓÚRRAFµÄÓ¢ÎÄ·Ò룬ÓÐЩ¼±£¬Âé·³°ïæ½âÊÍÏ£¬·Ç³£¸Ðл£¡
|
|
|
1.BRAF inhibitors drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling in oncogenic RAS revealing a paradigm of BRAF-mediated signaling that promotes tumour progression with clinical implications and highlighting the importance of understanding pathway signaling in clinical practice and of genotyping tumours prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects such as increased invasion¡£ ÕâÊÇÍêÕûµÄÒ»¾ä»°£¬ÓÐЩ³¤£¬Ö÷ÒªÏëÖªµÀRAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling £¬a paradigm of BRAF-mediated signalingÊÇʲôÒâ˼ 2.panRAF inhibitors with anti SRC activity |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸Öйúº£Ñó´óѧ£¬ÉúÎïѧ£¬301·Ö£¬Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
081700»¯¹¤Ñ§Ë¶µ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁÏѧ˶318Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
329Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ²ÄÁÏÇóµ÷¼Á£¬×Ü·Ö315£¨Ó¢Ò»£©
ÒѾÓÐ3È˻ظ´
0703»¯Ñ§µ÷¼Á
ÒѾÓÐ14È˻ظ´
320Çóµ÷¼Á0856
ÒѾÓÐ3È˻ظ´
307Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
288Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´

ÒøÉþ
ľ³æ (ÖøÃûдÊÖ)
Ö²Îï²ËÄñ
- Ó¦Öú: 144 (¸ßÖÐÉú)
- ¹ó±ö: 0.004
- ½ð±Ò: 2422.6
- É¢½ð: 961
- ºì»¨: 50
- Ìû×Ó: 1171
- ÔÚÏß: 266.2Сʱ
- ³æºÅ: 2681596
- ×¢²á: 2013-09-26
- ÐÔ±ð: GG
- רҵ: ÖÐÒ©×ÊÔ´

2Â¥2015-05-09 22:59:41
genhunter
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 387
- Ó¦Öú: 259 (´óѧÉú)
- ½ð±Ò: 9757.4
- É¢½ð: 10
- ºì»¨: 60
- Ìû×Ó: 2484
- ÔÚÏß: 1793Сʱ
- ³æºÅ: 2558361
- ×¢²á: 2013-07-22
- רҵ: Ö×Áö»¯Ñ§Ò©ÎïÖÎÁÆ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
BRAF inhibitors drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling in oncogenic RAS revealing a paradigm of BRAF-mediated signaling that promotes tumour progression with clinical implications and highlighting the importance of understanding pathway signaling in clinical practice and of genotyping tumours prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects such as increased invasion¡£ BRAF ÒÖÖÆ¼Á´ÙʹRAS-ÒÀÀµµÄBRAF½áºÏµ½CRAF, CRAFµÄ»î»¯£¬ÒÔ¼°Ö°© RASÐźŴ«µÝͨµÀÖеÄMEK-ERKÐźŴ«µÝ×÷ÓýÒʾÁËÒ»¸öÓÉ BRAF-½éµ¼µÄ£¬¸´ÔÓµÄÐźŴ«µÝ;¾¶£¬ÔÚ¾ßÓÐÁÙ´²Ñ§ÒâÒåµÄ´Ù½øÖ×Áö¶ñ»¯½ø³Ì(µÄ×÷ÓÃ), Í»³öÁËÁ˽â¸ÃÐźŴ«µÝ;¾¶ÔÚÁÙ´²Ó¦ÓÃÉϺÍÔÚʹÓÃBRFA-Ñ¡ÔñÐÔÒ©Îï֮ǰ¶ÔÖ×Áö×÷»ùÒò·ÖÀàµÄÖØÒªÐÔ£¬ÒÔ¼°¼ø±ðÄÄЩ»¼Õß¿ÉÄܶԴËÀàÒ©ÎïÓÐЧ£¬¶øÄÄЩ»á³öÏÖÔö¼ÓÀýÈçÖ×Áö×ªÒÆµÄ²»Á¼·´Ó¦¡£ |

3Â¥2015-05-09 23:20:27
ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
ÒøÉþ: ½ð±Ò+10, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл´óÉñµÄÄÍÐĽâ´ð£¬°ïÖúºÜ´ó 2015-05-10 12:40:36
ÒøÉþ: ½ð±Ò+10, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, лл´óÉñµÄÄÍÐĽâ´ð£¬°ïÖúºÜ´ó 2015-05-10 12:40:36
4Â¥2015-05-10 08:58:33













»Ø¸´´ËÂ¥